Trials / Completed
CompletedNCT00851929
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Medical University of South Carolina · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Hypothesis: Ambrisentan (Letairis ®) is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis
Detailed description
Primary Endpoint: Change in 6 minute walk distance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ambrisentan | ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2011-04-01
- Completion
- 2011-11-01
- First posted
- 2009-02-26
- Last updated
- 2018-08-02
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00851929. Inclusion in this directory is not an endorsement.